Conference Day One
November 12, 2024
PART ONE: FIND YOUR FUTURE PARTNER
Synopsis
Bringing you a targeted and scientifically aligned partnership opportunity from the start, this opening section brings key buyers together in a unique and unmissable format, to find your next partner and route to more capital.
Investment into Immune Reset, Rebalance & Reconstitution: Strategic Priorities & Emerging Trends to Deliver Temporary Cure or Cure
8:00 am Pharma Icebreaker:The Appetite Across Autoimmunity: Activity & Ambition for Immune Reset & Tolerance
Synopsis
- Discussing recent deal-making and current search and evaluation interests as a back-drop for conversations ahead
- Sharing insights into decision-making, due diligence, and data evaluation, specifically guidance on translational biomarkers to support clinical proof-of-concept studies
8:45 am Pharma Matchmaking Roundtables:
Synopsis
Immerse yourself in most valuable networking of the conference, and qualify yourself as a valuable prospect through face-to-face meetings with the pharma faculty. Rotate through pharma tables to understand how you align with search and evaluation interests, hear in-person feedback, and introduce your immunology technology to multiple stakeholders. Select your tables ahead of time and attend four 30-minute meetings across 2 hours of protected, face-to-face group networking time.
Melissa Matzelle, Associate Director, Immunology Search & Evaluation
Kevin White, Head of Immune Tolerance Therapeutics Discovery
Donmienne Leung, Director, AbbVie Ventures
Swarna Balasubramanian, Associate Director, S&E, Respiratory & Immunology
Tatiana Ort, Head of Bioscience Immunology
Neel Desai, Business Development & Licensing
Nicola La Monica, Senior Director, Strategic Search & Evaluation
Julie Di Paolo, Senior Director, Immunology Scientific Innovation Lead
Sean Evans, Senior Associate, Venture Investments
Kalpana Gupta Head of Immunology, Infectious Diseases & Metabolism Partnering, Regeneron
Saifur Rahman, Director, Business Development & Licensing
Chris Gagliardi, Principal, Sanofi Ventures
Jonathan Zombeck, Director Business Development
Julien Genovino, Associate Director, Global Business Development & Strategy
Emma Smith, Head of Immune Reset, UCB
Frank Brennan, Head of Immunology Translation, UCB
10:45 am Morning Break & Prescheduled 1-to-1 Networking using ONE Partnering
11:45 am Venture Panel: Differences in Corporate Venture Across Pharma
Synopsis
- Discussing the role of corporate venture capital across different organizations, how dramatic, and what are the differences?
- What are the checks and considerations of distinct corporate ventures?
- What level of strategic alignment is necessary?
12:15 pm Which Horse to Back? Progress, Deals & Company Analysis Across ImmuneMediated Disease Targets & Therapeutics, with a Focus on Cell Therapy & Immune Tolerance
Synopsis
- Reviewing the progress of cell therapies within the autoimmune disease landscape
- Sharing an analysis of the current cell therapies currently in preclinical and clinical
- Development
- Summarizing clinical and partnership developments to track the increasingly evolving space, and delving into what the field can expect for the road ahead
12:45 pm Lunch & Prescheduled 1-to-1 Networking using ONE Partnering
PART TWO: SHOWCASE YOUR SCIENCE
Synopsis
Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to showcase your pipeline, platform, and technologies to a room of aligned and qualified decision-makers.
Targeted Cell Elimination for Immune Reset: Comparing the Pivot & Promise of Cell Therapies, Cell Engagers & Complex Biologics in Autoimmunity
1:45 pm The Reset Hypothesis – is a Transient Deep Depletion Enough to Cure?
Synopsis
- Discussing data to date, to evaluate evidence for long-term depletion where B cells return without disease
- Assessing relative contributions of lymphoid depletion and CAR-T when administered in combination, and the degree at which lymphoid depletion regiment achieves the dramatic efficacy seen with cell therapy
- Debating the potential limited application of cell-engagers: is lymphoid depletion driving CAR-T efficacy and could we apply learnings to bispecific engager field
- Thinking beyond the CAR-T explosion, what are the non-CAR-T approaches to achieve reset? Discussing if similar efficacy can be achieved without CAR-T, applying the depth of B cell depletion to other cell types such as T cells or dendritic cells, and whether immune reset could be achieved without depletion at all
2:30 pm Expanding the Potential of B Cell Depleting Therapies Through Allogeneic CAR T
Synopsis
- Discussing history and evidence for B cell depleting strategies in autoimmune disease
- Sharing efforts to address immune rejection of allogeneic cells through hypoimmune technology
- Outlining potential advantages of SC291, Sana’s clinical-stage allogeneic CD19- targeted CAR T therapy, in patient experience, product consistency, and manufacturing scale
2:40 pm Mechanism of Action of CABA-201 Across Autoimmune Diseases
Synopsis
- Characterization of B-cell aplasia and reconstitution with CABA-201 across different autoimmune diseases
- Sharing up-to-date impact of CABA-201 on clinical outcomes
- Discussing CABA-201 characterization and pharmacokinetics
3:00 pm Afternoon Break & Prescheduled 1-to-1 Networking using ONE Partnering
4:00 pm Achieving Sufficiently Long Immune Reset: Comparing CAR-T & Cell-Engagers Targeting CD19
Synopsis
- Comparing and contrasting CAR-T and cell-engager modalities in the context of targeted cell elimination and cell dampening, how do they coexist in the treatment landscape?
- Assessing pre-conditioning, safety, depth, and duration of B cell depletion, manufacturing, and manufacturing-related issues
- Predictive biomarkers reflective of long-term efficacy for B cell depletion and immune reset
- Summarizing how to transition immune reset molecules from oncology to autoimmunity, including acceptable safety profiles and steps to progress to less severe autoimmune disease
5:00 pm Networking Drinks Reception:
Synopsis
Schedule your 1-to-1 meetings through Partnering One outside of the talks or enjoy an informal drinks networking reception with all attending and presenting companies to catch up with key stakeholders outside of the regular meeting and ahead of ACR or JPM in the conference calendar.